A powder formulation for use in a dry powder inhaler for the prevention and/or treatment of an inflammatory and/or obstructive airways disease, said formulation comprising: a carrier, comprising: (a) a fraction of coarse particles of a physiologically acceptable excipient having a mean particle size of at least 175 μm; and (b) a fraction of fine particles, consisting of a mixture of 90 to 99.5 percent by weight of particles of a physiologically acceptable excipient and 0.5 to 10 percent by weight of magnesium stearate, wherein at least 90% of all said fine particles have a volume diameter lower than 15 μm, wherein the weight ratio of said fine particles to said coarse particles is 5:95 to 30:70; and micronized particles of glycopyrronium bromide, formoterol fumarate dihydrate and beclometasone dipropionate as active ingredients, wherein said formulation is obtainable by a process comprising the steps of: (i) mixing said carrier, the particles of formoterol fumarate dihydrate and beclometasone dipropionate in a vessel of a shaker mixer at a speed of rotation not lower than 16 r.p.m. for a time of not less than 60 minutes, to obtain a first mixture; and (ii) adding the particles of glycopyrronium bromide to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not higher than 16 r.p.m. for a time of not more than 40 minutes; and whereby the mid-fine particle fraction of glycopyrronium bromide is higher than 25%. a carrier, comprising: (a) a fraction of coarse particles of a physiologically acceptable excipient having a mean particle size of at least 175 μm; and (b) a fraction of fine particles, consisting of a mixture of 90 to 99.5 percent by weight of particles of a physiologically acceptable excipient and 0.5 to 10 percent by weight of magnesium stearate, wherein at least 90% of all said fine particles have a volume diameter lower than 15 μm, wherein the weight ratio of said fine particles to said coarse particles is 5:95 to 30:70; and (a) a fraction of coarse particles of a physiologically acceptable excipient having a mean particle size of at least 175 μm; and (b) a fraction of fine particles, consisting of a mixture of 90 to 99.5 percent by weight of particles of a physiologically acceptable excipient and 0.5 to 10 percent by weight of magnesium stearate, wherein at least 90% of all said fine particles have a volume diameter lower than 15 μm, micronized particles of glycopyrronium bromide, formoterol fumarate dihydrate and beclometasone dipropionate as active ingredients, wherein said formulation is obtainable by a process comprising the steps of: (i) mixing said carrier, the particles of formoterol fumarate dihydrate and beclometasone dipropionate in a vessel of a shaker mixer at a speed of rotation not lower than 16 r.p.m. for a time of not less than 60 minutes, to obtain a first mixture; and (ii) adding the particles of glycopyrronium bromide to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not higher than 16 r.p.m. for a time of not more than 40 minutes; and (i) mixing said carrier, the particles of formoterol fumarate dihydrate and beclometasone dipropionate in a vessel of a shaker mixer at a speed of rotation not lower than 16 r.p.m. for a time of not less than 60 minutes, to obtain a first mixture; and (ii) adding the particles of glycopyrronium bromide to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not higher than 16 r.p.m. for a time of not more than 40 minutes; and